Mesenchymal stromal cells (MSC) can be exploited as cellular delivery vehicles for the enzymes converting non-toxic prodrugs to toxic substances. Because of their inherent chemoresistance, they exert potent bystander and antitumor effect. Here we show that the human adipose tissue-derived MSC expressing fusion yeast cytosine deaminase::uracil phosphoribosyltransferase (CD-MSC) in combination with 5-fluorocytosine (5FC) mediated a long-term tumor-free survival in the 83.3% of tumor-bearing animals. CD-MSC/ 5FC treatment induced cytotoxicity against model human melanoma cells EGFP-A375. Only 4% of the therapeutic CD-MSC cells eliminated 498.5% of the tumor cells in vitro. Long-term tumor-free survival was confirmed in 15 out of the 18 animals. However, repeatedly used CD-MSC/5FC therapeutic regimen generated more aggressive and metastatic variant of the melanoma cells EGFP-A375/Rel3. These cells derived from the refractory xenotransplants exhibited increased resistance to the CD-MSC/5FC treatment, altered cell adhesion, migration, tumorigenic and metastatic properties. However, long-term curative effect was achieved by the augmentation of the CD-MSC/5FC regimen along with the inhibition of c-Met/hepatocyte growth factor signaling axis in this aggressive melanoma derivative. In summary, the CD-MSC/5FC regimen can be regarded as a very effective antitumor approach to achieve long-term tumor-free survival as demonstrated on a mouse model of aggressive human melanoma xenografts.
INTRODUCTION
Cancer gene therapy has made a considerable progress in the past years, with several potential strategies improving its efficiency specifically in the aggressive difficult-to-treat malignant diseases. One of the approaches exploits the capability of exogenously introduced enzyme to convert a non-toxic substance to highly cytotoxic substance(s) and is referred to as a gene-directed enzyme/produg therapy (GDEPT). 1 Mesenchymal stromal cells (MSC) were proven to be suitable cellular vehicles for GDEPT approaches. [2] [3] [4] MSC represent a population with high proliferation capacity 5, 6 and the genetic engineering does not compromise their key properties; therefore they can serve for the cell-directed enzyme/prodrug therapy (CDEPT) in the antitumor treatment. 7 Moreover, several studies demonstrated the inherent chemoresistant properties of the MSC that enable them to withstand the suicide effect and thus prolong the bystander toxicity exerted on the neighboring tumor cells. [8] [9] [10] One of the most frequently used enzyme/prodrug combinations in GDEPT still remains the Herpes simplex virus thymidine kinase (HSV-TK) in combination with prodrug ganciclovir (GCV). 1 HSV-TK was expressed in the MSC and demonstrated an antitumor efficiency in the preclinical models either alone 11, 12 or in combination with a valproic acid as an augmentation agent. 13 Recently, Kim et al. 14 suggested that in order to achieve 100% survival of tumor-bearing mice and enhance antimetastatic effect, repeated injections of MSC/dTRAIL-TK were necessary. Different GDEPT approach is based on a combination of a rabbit carboxylesterase (rCE), which converts CPT-11 into SN-38, a potent topoisomerase 1 inhibitor. The enzyme was expressed in both the neural stem cells and the MSC and was shown to exhibit a strong antitumor effect against various tumor cells, including melanoma and medulloblastoma. 15, 16 Moreover, a long-term disease-free survival of the mice bearing disseminated neuroblastoma was reported after two rounds of the treatment with the neural stem cells expressing rCE/CPT-11. 17 The combination of a cytosine deaminase with a prodrug 5-fluorocytosine (5FC) is beneficial in the tumor cells expressing key molecular determinants of the sensitivity. 18 5FC is clinically approved antimycotic non-toxic drug that can be converted to a potent chemotherapeutic 5-fluorouracil (5FU) and its metabolites by non-mammalian enzymes. Nucleotide analogs of 5FU readily incorporate into the RNA and DNA by intracellular enzymes leading to high cytotoxicity. 19 We have previously demonstrated that a yeast fusion cytosine deaminase::uracil phosphoribosyl transferase (CD) as a transgene in combination with 5FC can exert strong antitumor effect, if delivered by human adipose tissuederived MSC in vivo. 20 This CDEPT combination will be referred to as CD-MSC/5FC further on. Antitumor effect was observed in human colon carcinoma, melanoma and prostate carcinoma. [20] [21] [22] Increased animal survival was reported after continuous intracerebroventricular delivery of 5FC along with the repeated administration of the therapeutic cells CD-MSC/5FC in the xenogeneic orthotopic setting. 23 The inhibition of c-Met/hepatocyte growth factor (HGF) signaling was previously shown to decrease the growth and metastasis formation in melanoma. 24 Its activation was recognized to induce a stem-like phenotype in prostate cancer 25, 26 and support stem-like phenotype in glioblastoma. 27 Therefore, we decided to test whether the targeting of this signaling axis in combination with the cytotoxic treatment resulted in a long-term anti-tumor effect. First, we investigated the potential of CD-MSC/5FC combination to achieve complete tumor eradication and a long-term tumor-free survival in our previously established immunodeficient mouse melanoma xenotransplant model. 22 Next we analyzed the properties of tumor cells, which escaped the treatment. Although the relapsed tumors exhibited highly aggressive and metastatic melanoma phenotype with increased resistance to the CD-MSC/5FC combination, the augmentation of cytotoxic treatment by inhibition of c-Met/HGF signaling axis restored the long-term curative outcome. Our data show that CD-MSC/5FC alone or in combination with targeted inhibitor achieved complete curative effect in melanoma-bearing animals.
RESULTS
Human melanoma cells A375 were chosen for the study based on their high responsiveness to the CD-MSC/5FC regimen, xenograft growth on immunodeficient mice in vivo even though these cell initially exhibited very low metastatic capability. 18, 22, 28 In order to confirm the extent of a bystander effect, relative cell fluorescence was measured on EGFP-A375 cells treated with the CD-MSC/5FC regimen in vitro. 29 The tumor cell fluorescence significantly decreased already 48 h after the treatment start (Figure 1a) , and within 5 days 499% of tumor cells were eradicated ( Figure 1b) . Next the timing of a 5FC prodrug administration in vivo was tested in order to examine a long-term antitumor efficiency of the CD-MSC/5FC therapy. The therapeutic CD-MSC were coinjected with the tumor cells EGFP-A375 in a ratio 1:10 (day 0), and the mice were treated with 2-day 5FC pulse (Figure 1c ). The early 5FC treatment (days 0-1) was efficient in an induction of the antitumor effect, although none of the tumors completely regressed. Prolonged 5FC administration resulted in a significant inhibition of the tumor growth in both the groups of animals treated with four doses of 5FC either on days 0-3 or days 4-7 postinoculation (Figure 1d ). In both the groups, 50% of tumors regressed completely and did not relapse for the 60 days of study duration. Delayed 5FC administration (starting on day 8) decreased tumor volume indicating that CD-MSC therapeutic cell were retained in the tumor mass for at least 8 days. We anticipate that rapid proliferation of melanoma cells caused that there was low ratio of therapeutic:tumor cells by day 8 to achieve significant antitumor effect.
Next, we evaluated the long-term efficiency of CD-MSC/5FC. Complete tumor regression could be achieved in all animals, although the tumors started to grow in the five out of the nine animals after a short period of tumor dormancy (Figure 2a ). Substantially higher long-term effect was achieved in the same setting with threefold lower initial number of the tumor cells. Complete regression was demonstrated in the 15 out of the 18 injected tumors, and tumors did not start growing until the end of the study (Figure 2b ). We decided to analyze further the responsiveness of the relapsed tumor cells, therefore the melanoma cells from the three xenografts were expanded in vitro, designated as EGFP-A375/Rel1 and treated with CD-MSC/5FC regimen in vitro. No increase in resistance to the regimen was detected in vitro (Table 1) . However, experiment in vivo unraveled that complete tumor eradication could be achieved in only 4 out of the 14 animals ( Figure 2b ). The tumor cells expanded from these relapses (EGFP-A375/Rel2) were used for the coinjection with the CD-MSC as described above. None of these growing tumors was eradicated upon 5FC administration in vivo although the antitumor effect was achieved. Tumor cells from these tumors were expanded in explant culture and were designated EGFP-A375/Rel3. Each derived cell population was confirmed to be G418 resistant, enhanced green fluorescent protein (EGFP) positive and CD146 (melanoma cell adhesion molecule) positive, thus confirming the melanoma origin. The direct comparison of the cell morphology suggested a change towards more spindle-shaped cells (Figure 3a) . Relapsed exponentially growing tumors were typically composed of 70-80% of viable (4,6-diamidino-2-phenylindole) DAPI-negative EGFP-positive cells (Figure 3b ). The absence of any CD-MSC in these cultures was confirmed by the absence of CD gene sequences detected by PCR as described elsewhere 22 (data not shown). Derived EGFP-A375/Rel1, Rel2 and Rel3 cells exhibited the same sensitivity to 5FU (Figure 3c and Table 1 ). However, the EGFP-A375/Rel3 cells were significantly more resistant to CDMSC/5FC treatment (Figure 3d ), which correlated with their refractoriness to CD-MSC/5FC in vivo (data summarized in Table 1 ). EGFP-A375/Rel3 exhibited higher tumorigenicity (Figure 3e) , and the antitumor efficiency of the therapeutic regimen was substantially reduced in vivo (Figure 3f ). This part of the study demonstrated some determinants important to consider for the therapeutic outcome. Importantly, single therapeutic regimen CD-MSC/5FC achieved a long-term tumorfree survival in the 83.3% of animals. The CDEPT treatment does not select for the chemoresistant tumor cells but favors the expansion of the tumor cell subpopulation that has higher tumorigenicity combined with the refractoriness to the particular therapy.
In order to dissect the effect of serial tumor cell passages from the effect of CD-MSC/5FC regimen, two more cell lines were prepared as depicted in Figure 4a . The EGFP-A375iv cells were derived in the absence of any treatment by the three consecutive rounds of serial subcutaneous (s.c.) passages in vivo. The EGFP-A375/MEA3 were derived by the three consecutive rounds of a systemic A375 administration from the metastatic lung foci as a highly metastatic derivative A375/MEA3 28 and by subsequent EGFP transduction. The direct comparison confirmed no difference in the proliferation potential, no significant difference in the 5FU sensitivity and no difference in the sensitivity of EGFP-A375iv or EGFP-A375/MEA3 to the CD-MSC/5FC treatment in comparison with the parental EGFP-A375 (data not shown). However, the adhesion assay confirmed significantly altered adhesion of the derived cells to the extracellular matrix (ECM) components in comparison with the bulk EGFP-A375 cells (Figure 4b ). EGFP-A375/ Rel3 cells exhibited significantly lower migratory potential in comparison with the bulk EGFP-A375 as determined in the wound-healing assay ( Figure 4c ). As it was previously suggested by Xu et al., 28 the majority of changes in the transcriptome leading to the increased aggressiveness in melanoma could be observed in the secreted and membrane bound proteins. Therefore the expression pattern of the 84 genes encoding various ECM proteins in the three melanoma derivatives was compared; and our data confirmed a differential expression pattern of the molecules involved in the cell-to-cell, cell-to matrix adhesion, proteases and other ECM molecules (Figure 4d , full names of the examined target genes are listed in the Supplementary Material). Serial treatment regimen of CD-MSC/ 5FC resulted in upregulation of contactin-1, extracellular matrix protein 1, intercellular adhesion molecule 1, integrins, laminin β3, matrix metalloproteinase 16 (MMP-16) and tissue-inhibitor of MMP 1 (TIMP1) in EGFP-A375/Rel3 cells when compared with the cells derived in the absence of any therapy. These alterations seem to contribute to the refractoriness to the CD-MSC/5FC regimen in vitro and in vivo.
The metastatic potential of the melanoma derived cells was further examined in a lung colonization assay. When the tumor cells were intravenously injected in SCID mice, each derivative formed tumor foci in the lungs as initially determined by a PCRbased detection of the human sequences on the mouse background. Direct comparison of the lung weight 20 days postinoculation indicated that the derived EGFP-A375iv cells were the most aggressive ones (Figure 4e ). The animal survival experiment unraveled that the EGFP-A375iv-injected group had indeed the shortest survival time (Figure 4f ), massive lung infiltration with the 51.2-77.1% EGFP+ cells detected by the flow cytometry and a lymph node infiltration in 3 out of the 13 animals. EGFP-A375/MEA3 derivative did not exhibit any infiltration of the CD-MSC/5FC treatment of EGFP-A375 L Kucerova et al lymph nodes (0/10), although tumor foci were massively growing in the lung parenchyma similarly to EGFP-A375/Rel3 (Figure 4g ). EGFP-A375/Rel3 animals had the tumor infiltration in the lungs present in each animal; and the lymph nodes were infiltrated in 7 out of the 13 animals examined. To summarize this part, relapsed melanoma cells after serial CD-MSC/5FC treatment were shifted towards the cell variant with the altered adhesion, migration, expression pattern of the ECM proteins, increased tumorigenicity and metastatic potential different from the cells derived in the absence of cytotoxic treatment. The inhibition by 5FC injected on days 0-1 was higher and time to exceed the volume of 100 mm 3 prolonged; however, none of the treated animals was tumor free. (d) Higher therapeutic efficiency was achieved when the animals injected as above were treated with four consecutive doses of 5FC starting either on day 0 or day 4. Animals that received 5FC starting on day 8 had lower tumor burden and time to exceed volume of 100 mm 3 was prolonged compared with untreated controls, but none of them remained tumor free. Contrastingly, 50% of animals that received 5FC early remained tumor free for the rest of the study, with the longest time to reach tumor volume of 100 mm 3 in the group treated on days 0-4. The day of the cell injection was designated day 0, **Po0.01, NS, not significant.
Further analysis of the molecular alterations in the derived EGFP-A375/Rel3 cells has shown upregulated expression of vascular endothelial growth factor receptor 2 (VEGFR2) and C-X-C motif chemokine receptor 4 (CXCR4; receptor of SDF-1α) but not c-Met receptor in comparison with bulk parental EGFP-A375 (PAR) or EGFP-A375iv (IV) cells (Figure 5a ). These targets were chosen to evaluate whether the inhibition of these signaling pathways reverted the therapeutic resistance. However, when AMD3100 (SDF-1α/CXCR4 signaling inhibitor) or Avastin (VEGFR2 inhibition) were combined with the CD-MSC/5FC treatment, the therapeutic efficiency could not be increased (Figure 5b ). AMD3100 did not significantly affect tumor volume or the time to exceed the tumor size of 100 mm 3 (33 vs 35 days, Figure 5c) . Surprisingly, the VEGFneutralizing antibody Avastin significantly increased the tumor volume and also shortened the median time for the tumors to exceed 100 mm 3 , thus further decreasing the therapeutic efficiency (22 vs 35 days, Figure 5d ). The Avastin treatment of EGFP-A375/Rel3 cells alone has shown stimulatory effect on the cell proliferation in vitro (Figure 5e ). Derivative EGFP-A375/Rel3 cells also exhibited decreased VEGF secretion in contrast to the parental EGFP-A375 or derivative EGFP-A375iv cells (Figure 5f ).
Our previous data indicated high expression of the c-Met receptor in melanoma cells A375, 29 which was retained in the examined derived cell lines ( Figure 5a ). Accordingly, the antiproliferative activity of the inhibitor SU11274, which is a small molecule tyrosine kinase inhibitor of c-Met signaling, was not substantially altered in the derived melanoma cells under the standard culture conditions (Figure 6a ). SU11274 did not compromise the efficiency of the CD-MSC/5FC treatment in vitro ( Figure 6b ). When melanoma cells were switched to melanosphere cultures as a surrogate assay for the melanoma-initiating cells, there was a significant inhibition of proliferation with the previously non-toxic concentrations of 0.5 μg ml CD-MSC/5FC treatment of EGFP-A375 L Kucerova et al treated animals with exponentially growing tumors (Figure 6g ). These data demonstrate a very efficient augmentation of the CDEPT approach by a tyrosine kinase inhibitor SU11274 in the melanoma model in vivo.
In conclusion, serial CD-MSC/5FC treatment in vivo selected for the melanoma cells with increased resistance, tumorigenic and metastatic properties. Specific differences in the derived cells, preferential lymph node infiltration and the migration potential enables further examination of specific anti-melanoma agents in the preclinical models. Moreover, we found the therapeutic strategy to augment the treatment of these aggressive tumors.
DISCUSSION
Antitumor efficiency of the CD-MSC/5FC regimen was already demonstrated in our previous studies. Short-term tumor regression was observed in each of the treated animals upon s.c. and intravenous administration including melanoma model. 7, [20] [21] [22] This study was focused on the evaluation whether the CD-MSC/5FC modality can achieve a long-term antitumor effect in the preestablished model of human melanoma xenografts. The melanoma A375 cells possess favorable intrinsic properties that render them most sensitive to the CD-MSC/5FC treatment from a panel of human tumor cells in vitro. 18 Bystander toxicity in the direct cocultures was indeed above 98.5% at the tumor-totherapeutic cell ratio 25:1 and was not achieved in any other melanoma cells (human M14 and M4Beu cells) tested in vitro (Figure 3d , Matuskova et al. 18 and unpublished data). This study further identified several key issues, which determined the treatment efficiency, such as the initial therapeutic-to-target cell ratio, timing of the prodrug administration and the initial number of the tumor cells. In order to achieve tumor-free survival in 480% of the animals, the ratio between the injected tumor and therapeutic cells had to be maintained at 5:1. The therapeutic CD-MSC proliferate at slower rate in comparison with the tumor cells, therefore it could be anticipated that the ratio of surviving therapeutic cells to tumor cells decreased rapidly in vivo, although being still sufficient to induce complete tumor regression. The timing of the 5FC prodrug administration also affected the outcome quite significantly. Amano et al. 30 suggested that in the HSV-TK-MSC/GCV system the prodrug GCV should be administered before the application of therapeutic cells. In our system, it was desirable not to administer the prodrug before the cell administration in order to avoid suicide effect in CD-MSC but not too late to have the efficient tumor-to-therapeutic cell ratio. Even short prodrug pulse of two doses was sufficient to affect tumor growth; however, only the treatment for at least 4 days in a row could eliminate the tumors completely in 50% of the animals with significant inhibition of tumor growth in the remaining ones (Figures 1c and d) . Tumor volume decrease was observed when 5FC treatment started on day 8 after the cell injection (Figure 1d ). We concluded that CD-MSC therapeutic cells were retained, but rapidly proliferating tumor cells in the presence of MSC 29 already outnumbered them, thus resulting in limited treatment efficiency.
Our data demonstrate that CD-MSC/5FC regimen achieved long-term complete tumor eradication in the treated animals. The differential efficiency in a high-dose versus low-dose injected groups (44.4% vs 83.3%, Figure 2b ) indicated that the regimen could efficiently eradicate the majority of tumor cells while sparing only those that could enter the state of cellular quiescence and dormancy. In some of the animals the cells did not re-enter into proliferative state; in some animals they gave rise to the exponentially growing tumor masses after a period of dormancy. The relapse frequency was demonstrated to correspond with the initial tumor burden while the treatment conditions and a ratio of the therapeutic-to-tumor cells was constant. We believe that immunodeficient mouse model actually underestimates the longterm antitumor efficiency of CDEPT, as it is accepted that the immune system has an important role in the eradication of tumor cells. 31 Immune system is activated in response to the antigens released from the necrotic cells, and it can further increase the effectiveness of the treatment by coping with the remaining (potentially dormant) cells. 32 The serial repeated treatment is quite of interest for further preclinical studies as we have proven that it brings therapeutic benefit. The gradual loss of therapeutic response, shortened time to tumor relapse and higher relapse frequency reflected the selection pressure exerted by the treatment. It resulted in a shift toward the cells that could finally withstand the bystander cytotoxicity. The different mechanisms of cytotoxicity between 5FU and CD-MSC/5FC regimen was involved in this process. 5FU can freely diffuse across the cell membranes, it is phosphorylated intracellularly and metabolized by the enzymes involved in the nucleotide metabolism. This is not altered in the derived cells as demonstrated by same sensitivity to 5FU. The CD-MSC are engineered to express the yeast fusion enzyme cytosine deaminase::uracil phosphoribosyltranserase. Thus the CD-MSC/ 5FC regimen relies on the synthesis of phosphorylated derivatives of 5FU that do not diffuse passively across the membranes and require functional gap junctional intercellular communication between the cells.
Tumor cells EGFP-A375/Rel3 derived after the three consecutive rounds of the CD-MSC/5FC therapy had higher tumorigenic potential in vivo similar to the cells expanded in the absence of any therapeutic selection in vivo (EGFP-A375iv). These two derivatives also share high metastatic ability but differ in migration, adhesion properties, response to the CD-MSC/5FC regimen in vitro and the expression profile of ECM proteins. Substantial increase in the expression of MMPs led us to the 
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hypothesis that this might contribute to increased resistance; however, the inhibitors of these enzymes did not prove any benefit for the treatment outcome in vitro (data not shown). The shift in cellular morphology (Figure 3a ) resembled a switch toward more mesenchymal-like phenotype previously also implicated in increased aggressiveness and stemness. [33] [34] [35] Although melanoma is not an epithelium-derived cancer, melanoma cell lines were reported to express various levels of regulatory genes of CD-MSC/5FC treatment of EGFP-A375 L Kucerova et al epithelial-to-mesenchymal transition. 34 We observed an increased expression of Snail1, Snail2 and Twist accompanied by E-cadherin decrease, induction of vimentin and endosialin at a molecular level, changes that were previously linked to tumor progression in melanoma. 35, 36 The shift in the epithelial-to-mesenchymal transition regulator expression might contribute to the increased tumorigenicity of the relapsed CD-MSC/5FC-refractory cells. 37, 38 We have interrogated the possibility of the enrichment for the melanoma-initiating cells or the cells with the putative melanoma stem cells markers in derived cells. 39 Bulk A375 melanoma cells express high levels of pluripotency markers such as Oct3/4, Nanog and Sox2, corresponding to their highly tumorigenic nature. Neither these nor the expression of other markers such as CD133, ABCB5 or ABCG2 was changed in EGFP-A375/Rel3 cells in comparison with the parental or EGFP-A375iv as determined in the expression analysis and stem cell arrays (unpublished data). Our results suggest that the detected alterations in the interactions of tumor cells with the ECM were crucial both for the alterations of their biological behavior and therapeutic response. Some of the upregulated targets such as contactin-1, osteonectin (SPARC) or tenascin C can be linked to the aggressive nature of the derived EGFP-A375/Rel3 cells. [40] [41] [42] The refractoriness to the CD-MSC/5FC regimen is also likely to lie in the less efficient uptake of the toxic metabolites as a result of altered tumor-stromal interaction or resistance to apoptosis induction by ECM proteins. 43 Derived tumor cells differently interact with ECM, have altered homocellular tumor-tumor and heterocellular tumorstromal interactions, which subsequently contribute to the adhesion-mediated apoptosis resistance. [44] [45] [46] Shifted balance between MMPs and their inhibitors (increased expression of MMP-1, -11, -14, -16, TIMP-1 and decreased MMP-2) indicates a different matrix remodeling, 47 potentially leading to anoikis resistance in melanoma cells by mechanism similar to the one suggested by Toricelli et al. 48 CD-MSC/5FC exerts potent bystander effect in the cells with functional gap junction intercellular communication. 18 Higher expression of connexin-interacting proteins integrins β1 and β3 (ITGB1, ITGB3), α-catenin and β-catenin (CTNA1 and CTNB2) in EGFP-A375/Rel3 cells versus EGFP-A375iv clones may potentially contribute to resistance to apoptosis induction by channel modification. 49, 50 We hypothesize that ECM-and cell adhesion-mediated apoptosis resistance together with a modulation of gap junction intercellular communication shifts the therapeutic efficiency by a complex mechanism that will be the subject of further investigation.
These findings were further supported by the study published by Xu et al., 28 who suggested that extracellular and membranebound protein expression was dramatically changed in more aggressive metastatic melanoma cells. Similar tumor cell variants can be derived also from the other types of tumors such as pancreatic cells in vivo. 51 Direct comparison of the different melanoma isolates in a lung colonization assay confirmed that the serial s.c. or intravenous passages of melanoma cells in vivo selected for the cells, which exhibited high metastatic capabilities with worse phenotype in the absence of any therapeutic pressure. Multiple changes in the transcriptome of these highly tumorigenic cells render them rather difficult to target as demonstrated by the combination strategy involving VEGFR2 or CXCR4 inhibition. The neutralizing anti-VEGF antibody was administered in an attempt to augment the therapeutic efficiency, but it actually even further shortened the time for the tumors to achieve the size of 100 mm 3 . This outcome was due to the Avastin-mediated increase in EGFP-A375/Rel3 proliferation, while the cells alone had decreased VEGF secretion and responded to the treatment with recombinant VEGF by inhibition of proliferation (data not shown). Adamcic et al. 52 recently demonstrated similar effect in melanoma WM115 cells treated with bevacizumab (Avastin). Bevacizumab increased cell proliferation in vitro and was shown to be an effective antiangiogenic but not antitumorigenic agent in vivo. It is not clear whether the intracrine signaling loop or other mechanism might be involved in this process. 53, 54 In contrast to these data, a small-molecule inhibitor of the c-Met signaling prevented a relapse of the CD-MSC/5FC-treated melanoma xenografts. Our interpretation is that the CD-MSC/5FC regimen serves as a very efficient cytotoxic in situ strategy. All animals responded, and a majority of them was without any detectable tumors for a short time period. However, the dormant/quiescent melanoma cells capable of tumor growth initiation were still present. The inhibitor SU11274 inhibited reactivation of tumor growth; so we assume that the inhibition of HGF/c-Met signaling axis might be considered as a strategy to target melanoma-reinitiating cells. This is consistent with our finding that the inhibitor can significantly compromise proliferation in non-adherent melanosphere culture conditions. The antitumor and antimetastatic properties of SU11274 in melanoma were reported previously, 24 but the effect was not curative as the rapidly proliferating melanoma cells were not targeted by the inhibitor. It is possible that c-Met/HGF signaling axis is critical for the melanoma-initiating cells, similar to the prostate cancer stem cells which have an autocrine HGF signaling. 26 The role of c-Met/HGF signaling remain 
to be examined in the prospectively isolated melanoma stem cells and in the clinical setting. 55 Our data suggested that the inhibition of c-Met/HGF might be exploited to augment anti-melanoma treatment in order to achieve long-term cure.
Taken together, our study described several determinants of the therapeutic efficiency of the CDEPT and further focused on the properties of relapsed cells. We believe that our model at least partially corresponds to the clinical situation, when the tumor properties evolve under the therapeutic pressure. 56 We think that clones with increased tumorigenicity and metastatic behavior are already present in the bulk melanoma cells and do not arise in response to therapy. 57 These cells have the survival advantage, and they are enriched for in the later stages of disseminated metastatic disease. 58 Importantly, repeated use of the same regimen did not produce typical chemoresistant cells and still exerted antitumor effect. Based on the molecular analysis, several agents were tested as a therapy augmentation but failed to show any benefit. The combination with antiangiogenic antibody even hindered antitumor response. More importantly, we have shown a very efficient combination strategy to achieve long-term curative effect in xenografts derived from aggressive melanoma by augmentation with agent interfering with melanoma-initiating cells. Our experiments and mouse models were designed to assess the determinants of the therapeutic efficiency with a simple rapid high-throughput readout strategy. Next step will be to determine whether this can be validated in the therapeutic setting.
CONCLUSION MSC-mediated gene-directed enzyme/prodrug therapy alone or in combination with other antitumor strategies is efficient in many different tumor models and experimental settings. We demonstrated the capability of CD-MSC/5FC to achieve long-term tumorfree survival in xenotransplant melanoma model. Our study stresses the importance of the optimal treatment timing and augmentation in order to achieve the highest antitumor response. The analysis of molecular and biological properties in the relapsed tumor cells demonstrated their refractoriness to the therapeutic regimen in vitro and tumorigenic and highly metastatic behavior in vivo. Our experiments present two novel melanoma-derived cell lines suitable for further evaluation of the antimelanoma therapeutic strategies. They might serve for the future studies to dissect and target the molecules responsible for their aggressiveness and the metastatic properties.
MATERIALS AND METHODS Chemicals
5FC, 5FU, AMD3100 and SU11274 were purchased from Sigma-Aldrich (St Louis, MO, USA). Avastin (Bevacizumab, Roche, Basel, Switzerland) was kindly provided by the National Cancer Institute, Bratislava, Slovakia.
Cells and cell lines
Human melanoma cell line A375 (ECACC No. 88113005) stably expressing EGFP was prepared and cultured as described.
22 A375/MEA3 derivative was obtained from the laboratory of Richard O Hynes (Center for Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA). 28 EGFP-A375/MEA3 cells stably expressing EGFP were prepared by the retrovirus transduction as described in our publication 29 with a modification according to the subsequent work. 8 EGFP expression was confirmed by fluorescent microscopy and flow cytometry on the BD Canto II cytometer (Becton Dickinson, Franklin Lakes, NJ, USA) equipped with the FACSDiva program. FCS Express software was used for the evaluation.
Melanosphere culture was performed in ultra-low adherent plates and serum-free medium supplemented as described in detail elsewhere 59 for 14 days. Melanospheres were collected by centrifugation, dissociated and single-cell suspension was used for further experiments.
The therapeutic CD-MSC were prepared and expanded as previously described in detail. 8, 20, 59 Cell viability assays
Quadruplicates of 3000 melanoma cells per 100 μl per well were seeded in black-walled 96-well plates (Greiner Bio-One Intl. AG, Kremsmunster, Austria) overnight. For the 5FU treatments, 100 μl culture medium with diluted drug was added to the cells for 5 days. In the coculture experiments, the CD-MSC and tumor cells were mixed at the indicated ratios, plated 3000 cells per 100 μl per well and let to adhere overnight. Next day, the culture medium was supplemented with the 5FC to the final concentration of 50 μg ml − 1 and cultured for 2-5 days before evaluation. Alternatively, 2500 melanoma cells per 50 μl per well were mixed with serially diluted CD-MSC in 50 μl culture media, supplemented with inhibitor SU11274 as indicated, let to adhere overnight, supplemented with the 5FC to the final concentration of 100 μg ml 
Kinetic proliferation and migration measurements
Three thousand melanoma cells per well were seeded in 96-well plates (CytoOne, Starlab GmbH, Hamburg, Germany) and incubated in the presence or absence of 62.5 μg ml − 1 Avastin. Images were taken every 3 h by the IncuCyte ZOOM Kinetic Imaging System (Essen BioScience, Welwyn Garden City, UK). Cell confluence was evaluated by the IncuCyte ZOOM software 2012A based on the appropriate processing definitions. Data were expressed as mean relative cell confluence of quadruplicates ± s.d.
For the migration assays, 65 000 cells per well were plated in sextuplicates on ImageLock 96-well plates (Essen BioScience) and let to adhere for 16 h. The confluent monolayers were wounded with a woundmaking tool, washed twice and supplemented with the fresh culture medium. Images were taken every 2 h for the next 48 h in the IncuCyte ZOOM Kinetic Imaging System (Essen BioScience). Cell migration was EGFP-A375/Rel3 cells were directly cocultured with CD-MSC in the presence of 50 μg ml − 1 5FC combined either with SU11274 or vehicle (dimethyl sulfoxide (DMSO)) for 6 days. Relative viability was determined as above. No significant difference was observed in SU11274-treated cells. (c) SU11274 significantly inhibited proliferation of melanoma cells EGFP-A375/Rel3 in non-adherent conditions. Melanospheres were cultured for 14 days, and the total cell number was determined, *P o0.05. (d) Single-cell suspensions were prepared from SU11274-treated or vehicle-treated melanospheres and plated in standard adherent culture conditions. Cell proliferation was determined by the Incucyte live-cell kinetic imaging system. SU11274-pretreated cell have significantly decreased relative confluence of the cultures corresponding to the lower proliferation potential. (e) Decreased proliferation of the cells was confirmed by luminescent cell viability assay and confirmed to be significantly lower in the cells after SU11274 pretreatment in non-adherent culture conditions, *P o0.05. (f) Nude mice were coinjected with the EGFP-A375/Rel3 and CD-MSC and treated with 0.5 mg kg − 1 day − 1 SU11274 or vehicle (2% DMSO in PBS) daily i.p. starting on day 0. SU11274 significantly increased the tumor growth in comparison with mock-treated animals injected with or without CD-MSC, *Po 0.05. (g) Nude mice were coinjected as in panel (f) and treated with 500 mg kg − 1 day − 1 5FC daily with or without SU11274. Tumor growth inhibition was achieved in all the animals, and the proportion of tumor-free animals was calculated at each time point. EGFP-A375/Rel3-and CD-MSC-injected animals, which were either treated with inhibitor or vehicle, developed tumor by day 3 and had to be killed by day 27 ( †). SU11274 co-administration with 5FC significantly increased the proportion of tumor-free animals and achieved complete cure in 9 out of the 10 injected animals at the experiment end point.
evaluated by the IncuCyte ZOOM software based on the wound width and the wound confluence measurements; data were expressed as means ± s.d. Experiment was repeated four times; the representative result is shown.
Expression analysis
Quantitative PCR was performed as previously described in detail. 29, 60 For the expression array, total RNA from the cells was isolated by the Agilent Total RNA isolation Mini kit (Agilent Technologies, Santa Clara, CA, USA), reverse transcribed with the RT 2 First strand kit (SABiosciences-a QIAGEN Company, Frederik, MD, USA) and mixed with the RT 2 SYBR Green qPCR Mastermix (SABiosciences-a QIAGEN Company) . The ECM and adhesion molecule expression profile was analyzed by the RT 2 Profiler PCR Array Human Extracellular Matrix and Adhesion Molecules PAHS-013 (SABiosciences-a QIAGEN Company) on the Bio-Rad CFX96 (Bio-Rad, Hercules, CA, USA) and evaluated by an Excel-based PCR Array Data Analysis Software (Bio-Rad). Values ⩾ 35 were set to 35. For every melanoma derivative, 2log ratios were determined between the examined derived cells and bulk A375.
VEGF secretion
The secretion of VEGF was determined in the cell-free supernatants collected from 5 × 10 4 melanoma cells per well (12-well plates) plated in 1 ml of serum-free medium by the human VEGF Quantikine Immunoassay (R&D Systems Inc., Minneapolis, MN, USA) on a plate reader X-MARK (BioRad). The experiment was performed twice in triplicates, and the representative outcome is shown.
ECM adhesion
Cell adhesion was examined by CytoSelect 48-well cell adhesion assay (ECM array, colorimetric format, Cell Biolabs, San Diego, CA, USA). A total of 100 000 serum-starved cells per well were plated in the 150 μl of serumfree medium supplemented with 0.5% bovine serum albumin, 2 mM MgCl 2 and 2 mM CaCl 2 and incubated for 1 h. Cells were carefully washed and stained with cell stain solution. The absorbance corresponding to the number of adherent cells was measured by determining opticl density at 560 nm on a plate reader X-MARK (Bio-Rad). The experiment was performed in duplicates, and the representative outcome is shown.
In vivo animal studies
Six-week-old athymic nude mice (Balb/c-nu/nu) were used in accordance with the institutional guidelines under the approved protocols. It was determined in the preliminary studies that the 10 6 A375 or EGFP-A375 cells exhibit 100% tumor penetrance when injected s.c. For the evaluation of timing of the 5FC treatment, 1 × 10 6 EGFP-A375 were coinjected with 1 × 10 5 CD-MSC in 100 μl of PBS s.c. into the flank (n = 6/group). Animals were subsequently treated with the 5FC diluted in PBS (500 mg kg − 1 day − 1 ) intraperitoneally (i.p.) according to the timing schedule. Animals were regularly monitored for tumor growth.
In the high-dose coinjection study, 1.5 × 10 6 A375 were mixed with 3 × 10 5 CD-MSC and injected s.c. One group of animals (n = 8-9/group) was treated with the 5FC (500 mg kg − 1 day − 1 ) i.p. for three consecutive 5-day rounds with 2 days break starting on day 2. In the low-dose coinjection study, 5 × 10 5 EGFP-A375 (n = 18), EGFP-A375/Rel1 (n = 14) or EGFP-A375/ Rel2 (n = 10) cells were mixed with the 1 × 10 5 CD-MSC and injected s.c. Animals were treated with the 5FC as above. In the absence of 5FC administration, each animal of the untreated group developed tumor and had to be killed within 30 days. In order to determine the tumor initiation frequencies, 2 × 10 5 EGFP-A375, EGFP-A375/Rel1, EGFP-A375/Rel2 or EGFP-A375/Rel3 (n = 5-6/group) were injected s.c.
Independent experiment was initiated with the 5 × 10 5 EGFP-A375/Rel3 cells mixed with the 1 × 10 5 CD-MSC and injected s.c. Animals were treated with the 5FC as described above. Animals were subsequently divided into the following groups (n = 8-10/group): 5FC alone, 5FC with 1.25 mg kg − 1 AMD3100 every other day s.c., and 5FC with 1 mg kg − 1 Avastin i.p. twice a week according to the preestablished protocol. 29 Two groups of animals received 1.25 mg kg − 1 AMD3100 every other day s.c. or 1 mg kg − 1 Avastin i.p. twice a week alone. In an independent experiment, animals were treated with 5FC in combination with a daily dose of 0.5 mg ml − 1 SU11274 i.p. diluted in 2% dimethyl sulfoxide in PBS or 5FC with vehicle. Control group of animals was injected with vehicle alone or in combination with 5FC i.p. The inhibitor SU11274 or vehicle was administered for 4 consecutive weeks starting on day 0.
EGFP-A375iv cells were derived after the three consecutive rounds of the 5 × 10 5 EGFP-A375 cell injection s.c., followed by the EGFP+ cell expansion from the xenotransplants with volume~1 cm 3 and reinjection without any treatment.
Animals were regularly inspected for the tumor incidence and considered tumor-free when no palpable rigid structure exceeding 1 mm 3 could be detected. Growing tumors were measured by the caliper, and tumor volume was calculated according to the formula volume = length x width 2 /2. Results were evaluated as mean volume ± s.d. Animals were killed when the tumors exceeded 1 cm 3 in accordance with the ethical guidelines or at the experiment end point on day 90. Animals were designated tumor free at the experiment end point when no tumor growth was detectable in any of the organs examined by histology (lymph nodes, lung, liver, spleen, brain).
Xenograft explant culture
For the analysis of melanoma cells obtained from the relapses, animals were killed at the experiment end point, and the xenografts were excised. Tumors were mechanically dissociated, homogenized in the accutase solution (PAA Laboratories GmbH, Pasching, Austria) with the GentleMACS homogenizer (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) and seeded in a standard culture medium for the melanoma cell expansion. Expanded growing cells were confirmed to exhibit G418 resistance, uniform expression of EGFP by fluorescent microscopy and flow cytometry. Cells were labeled with DAPI to identify DAPI-negative viable cells. There was no decrease in the intensity of the EGFP fluorescence in the derived cells, and they were verified to be positive for the melanoma differentiation antigen CD146 (melanoma cell adhesion molecule, ⩾ 99% positivity) by flow cytometry. The antibody anti-CD146-APC (Miltenyi Biotec) was used.
Lung colonization assay
Six-to-eight-weeks-old SCID beige mice (CD17 Cg-Prkdscid Lystbg/Crl) were injected with the 5 × 10 5 EGFP-A375, EGFP-A375iv, EGFP-A375/MEA3 or EGFP-A375/Rel3 intravenously into the tail vein (n = 6-8/group). Animals were killed by day 20 and inspected for the tumor foci in the internal organs. Lung weight was recorded. Lungs and/or macroscopically visible infiltrated lymph nodes were mechanically dissociated, accutase digested and single-cell suspensions were used for the subsequent flow cytometric analysis to determine the EGFP+ tumor cell proportions. Lymph node infiltration was verified by histopathological examination.
In the independent series of experiments, SCID mice were injected intravenously as described above (n = 7-8/group) and monitored to determine the mouse survival. Macroscopic examination of tumor foci formation in dead animals was performed by necropsy; samples from the lungs and positive lymph nodes were taken for the DNA analysis and flow cytometric verification.
Statistical analysis
The Student's two-sample t-test was used for hypothesis testing for the difference in means of two samples, assuming that both samples come from a normal distribution with the s.ds. unknown but assumed equal. The Mann-Whitney U test was used to perform a two-sided test of the hypothesis that two independent samples come from distributions with equal medians. Survival analysis was evaluated by log-rank test (Mantel--Cox) to determine the significance. P-values with Po 0.05 were considered to be statistically significant.
